论文部分内容阅读
Objective To investigate the therapeutic potential of high-dase immunoglobulin (HIG) in experimental allergic neuritis (FAN) to provide a theoretical basis of its clinical use in the treatment of human inflammatory emyelinating neuropathies.rnMethods Female Lewis rats were induced to EAN,and divided into experimental and control groups. The rats were treated with either 0.3 g/kg.day-1 of IgG oran equivalent volume of 0.15oVL glycine. Clinicst,electrophysiologic,and histologic evaluations were carried out in a blind fashion.rnResults Clinically, rars treated with fgG had significantly less severe symptoms (P＜0.001) and slower progression (P＜0.001) than controls.rnElectrophysiologically, the mean conduction latency of the experimental group was significantly shorter than controls (P＜0.05).Histologically,rats treated with lgG prepared from normal Lewis rats had a significantly rnlower percentage of damyelinated fibem (P=0.01)and total abnormal fibers (P＜0.001) than ontrels,Statistically,clinicat, electrophysiologic and moqrphologic data were all significantly correlated.rnConcluslons The EAN animal model is reliable for observation of HIG effects, and useful to provide data for clinical work. HIG has a significant therapeutic effect in EAN when given soon after disease onset. Itcan reduce clincal disease severity and decrease the number of demyelinated fibers as well as the number of total abnormal fibers. For the current ctroversy over whether HIG is effective, the results of this research support the clinical use of HIG in human damyelinating neuropathy.